Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03889639 · ClinicalTrials.gov registry record · Phase 2
Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT03889639 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 130 participants.
The verdict
NCT03889639, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
Primary Objective: To determine the dose-response relationship for SAR442168 to reduce the number of new active brain lesions. Secondary Objectives: * To evaluate efficacy of SAR442168 on disease activity as assessed by imaging measures. * To evaluate the safety and tolerability of SAR442168.
Interventions
- DRUG Placebo
- DRUG SAR442168
- DRUG Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2019-03-29 |
| Est. Completion | 2020-01-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03889639
The ClinicalTrials.gov registry entry for NCT03889639 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03889639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03889639 about?
NCT03889639 is a clinical study titled "Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis". Primary Objective: To determine the dose-response relationship for SAR442168 to reduce the number of new active brain lesions. Secondary Objectives: * To evaluate efficacy of SAR442168 on disease activity as assessed by imaging measures. * To evaluate the safety and tolerability of SAR442168.
What is the current status of trial NCT03889639?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2019-03-29. Estimated completion is 2020-01-02.
What interventions are being tested in trial NCT03889639?
The interventions under investigation include: Placebo (DRUG), SAR442168 (DRUG), Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI) (DRUG).
Who is sponsoring clinical trial NCT03889639?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.